Targeting liver tumors by administering liposomal doxorubicin into the hepatic artery

Yiyu Zou, I. Horikoshi, M. Ueno, X. Gu, Roman Perez-Soler

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The plasma levels, organ distribution, and in vivo anti-tumor activity of liposomal doxorubicin administered i.v. or i.a. (hepatic) in rats bearing W256 liver tumors were studied. I.a. administration of liposomal doxorubicin resulted in 4-fold and 1.3-fold higher liver tumor and liver parenchyma doxorubicin levels, respectively, than i.v. administration, thus suggesting a more preferential distribution of liposomal doxorubicin into the liver tumor with i.a. administration. By contrast, the heart, spleen, and plasma AUCs were decreased 3.8-, 3.2-, and 16-fold, respectively, after i.a. administration. Cumulative urinary excretion at 8 hr was also 14 times lower in animals that received liposomal doxorubicin i.a. In good correlation with these findings, i.a. administration markedly enhanced the anti-tumor effect of liposomal doxorubicin against liver W256 tumors as measured by tumor growth inhibition 5 days after treatment (-16% for i.a. administration vs. +89% for i.v. administration, p ≤ 0.05) and prolongation of survival (ILS: 108% for i.a. administration vs. 26% for i.v. administration, p ≤ 0.05). Our results show that i.a. administration of liposomal doxorubicin results in preferential distribution of the anti-tumor agent into the tumor tissue and increased anti-tumor activity, while increasing the cardioprotective effect of the liposome carrier by decreasing the plasma peak and heart-tissue levels of the drug.

Original languageEnglish (US)
Pages (from-to)232-237
Number of pages6
JournalInternational Journal of Cancer
Volume51
Issue number2
DOIs
StatePublished - 1992
Externally publishedYes

Fingerprint

Hepatic Artery
Liver
Neoplasms
liposomal doxorubicin
Liposomes
Doxorubicin
Area Under Curve
Spleen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Targeting liver tumors by administering liposomal doxorubicin into the hepatic artery. / Zou, Yiyu; Horikoshi, I.; Ueno, M.; Gu, X.; Perez-Soler, Roman.

In: International Journal of Cancer, Vol. 51, No. 2, 1992, p. 232-237.

Research output: Contribution to journalArticle

@article{1e6e2007118643b7bede03e463a63293,
title = "Targeting liver tumors by administering liposomal doxorubicin into the hepatic artery",
abstract = "The plasma levels, organ distribution, and in vivo anti-tumor activity of liposomal doxorubicin administered i.v. or i.a. (hepatic) in rats bearing W256 liver tumors were studied. I.a. administration of liposomal doxorubicin resulted in 4-fold and 1.3-fold higher liver tumor and liver parenchyma doxorubicin levels, respectively, than i.v. administration, thus suggesting a more preferential distribution of liposomal doxorubicin into the liver tumor with i.a. administration. By contrast, the heart, spleen, and plasma AUCs were decreased 3.8-, 3.2-, and 16-fold, respectively, after i.a. administration. Cumulative urinary excretion at 8 hr was also 14 times lower in animals that received liposomal doxorubicin i.a. In good correlation with these findings, i.a. administration markedly enhanced the anti-tumor effect of liposomal doxorubicin against liver W256 tumors as measured by tumor growth inhibition 5 days after treatment (-16{\%} for i.a. administration vs. +89{\%} for i.v. administration, p ≤ 0.05) and prolongation of survival (ILS: 108{\%} for i.a. administration vs. 26{\%} for i.v. administration, p ≤ 0.05). Our results show that i.a. administration of liposomal doxorubicin results in preferential distribution of the anti-tumor agent into the tumor tissue and increased anti-tumor activity, while increasing the cardioprotective effect of the liposome carrier by decreasing the plasma peak and heart-tissue levels of the drug.",
author = "Yiyu Zou and I. Horikoshi and M. Ueno and X. Gu and Roman Perez-Soler",
year = "1992",
doi = "10.1002/ijc.2910510211",
language = "English (US)",
volume = "51",
pages = "232--237",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Targeting liver tumors by administering liposomal doxorubicin into the hepatic artery

AU - Zou, Yiyu

AU - Horikoshi, I.

AU - Ueno, M.

AU - Gu, X.

AU - Perez-Soler, Roman

PY - 1992

Y1 - 1992

N2 - The plasma levels, organ distribution, and in vivo anti-tumor activity of liposomal doxorubicin administered i.v. or i.a. (hepatic) in rats bearing W256 liver tumors were studied. I.a. administration of liposomal doxorubicin resulted in 4-fold and 1.3-fold higher liver tumor and liver parenchyma doxorubicin levels, respectively, than i.v. administration, thus suggesting a more preferential distribution of liposomal doxorubicin into the liver tumor with i.a. administration. By contrast, the heart, spleen, and plasma AUCs were decreased 3.8-, 3.2-, and 16-fold, respectively, after i.a. administration. Cumulative urinary excretion at 8 hr was also 14 times lower in animals that received liposomal doxorubicin i.a. In good correlation with these findings, i.a. administration markedly enhanced the anti-tumor effect of liposomal doxorubicin against liver W256 tumors as measured by tumor growth inhibition 5 days after treatment (-16% for i.a. administration vs. +89% for i.v. administration, p ≤ 0.05) and prolongation of survival (ILS: 108% for i.a. administration vs. 26% for i.v. administration, p ≤ 0.05). Our results show that i.a. administration of liposomal doxorubicin results in preferential distribution of the anti-tumor agent into the tumor tissue and increased anti-tumor activity, while increasing the cardioprotective effect of the liposome carrier by decreasing the plasma peak and heart-tissue levels of the drug.

AB - The plasma levels, organ distribution, and in vivo anti-tumor activity of liposomal doxorubicin administered i.v. or i.a. (hepatic) in rats bearing W256 liver tumors were studied. I.a. administration of liposomal doxorubicin resulted in 4-fold and 1.3-fold higher liver tumor and liver parenchyma doxorubicin levels, respectively, than i.v. administration, thus suggesting a more preferential distribution of liposomal doxorubicin into the liver tumor with i.a. administration. By contrast, the heart, spleen, and plasma AUCs were decreased 3.8-, 3.2-, and 16-fold, respectively, after i.a. administration. Cumulative urinary excretion at 8 hr was also 14 times lower in animals that received liposomal doxorubicin i.a. In good correlation with these findings, i.a. administration markedly enhanced the anti-tumor effect of liposomal doxorubicin against liver W256 tumors as measured by tumor growth inhibition 5 days after treatment (-16% for i.a. administration vs. +89% for i.v. administration, p ≤ 0.05) and prolongation of survival (ILS: 108% for i.a. administration vs. 26% for i.v. administration, p ≤ 0.05). Our results show that i.a. administration of liposomal doxorubicin results in preferential distribution of the anti-tumor agent into the tumor tissue and increased anti-tumor activity, while increasing the cardioprotective effect of the liposome carrier by decreasing the plasma peak and heart-tissue levels of the drug.

UR - http://www.scopus.com/inward/record.url?scp=0026578756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026578756&partnerID=8YFLogxK

U2 - 10.1002/ijc.2910510211

DO - 10.1002/ijc.2910510211

M3 - Article

C2 - 1568791

AN - SCOPUS:0026578756

VL - 51

SP - 232

EP - 237

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -